natgillin/translations-raw huggingface dataset:
The bioaccumulation study in fish was performed in accordance with the OECD guideline no. 3053 via aqueous exposure under flow-through conditions with continuous renewal of the test media at nominal [3H]-moxidectin concentrations of 0.00055 and 0.0011 μg/l (based on an acute LC50 (the concentration of a test substance which results in a 50% mortality of the test species) value of 0.11 µg/l).
Študijo kopičenja v organizmih pri ribah so izvedli v skladu s smernico OECD št. 3053 prek izpostavljenosti v vodi pod pretočnimi pogoji s stalnim obnavljanjem preskusnega medija z nazivnima koncentracijama [3H]-moksidektina 0,00055 in 0,0011 μg/l (na osnovi akutne vrednosti LC50 (koncentracije testne snovi, ki povzroči 50-odstotno smrtnost testne vrste) 0,11 µg/l).
Veterinary medicinal products containing moxidectin as a sole active substance or in combination with another antiparasitic active substance(s) (e.g. triclabendazole or praziquatel) are widely used for the treatment and prevention of internal and external parasitic infections in foodproducing animals and companion animals.
Zdravila za uporabo v veterinarski medicini, ki vsebujejo moksidektin kot edino zdravilno učinkovino ali v kombinaciji z drugo(-imi) antiparazitsko(-imi) zdravilno(-imi) učinkovino(-ami) (npr. triklabendazolom ali prazikantelom), se pogosto uporabljajo za zdravljenje in preprečevanje notranjih in zunanjih parazitskih infestacij pri živalih za proizvodnjo živil in hišnih živalih.
Clostridium chauvoei, Corynebacteriu m pseudotubercul osis
Clostridium chauvoei, Corynebacteriu m pseudotubercul osis raztopina za injiciranje
It is noted that according to the CVMP reflection paper on the authorisation of VMPs containing PBT or vPvB substances (EMA/CVMP/448211/2015)17 further measures intended to ensure responsible use of antiparasitic veterinary medicinal products, for example, targeted selective treatment of individual animals on farm level, are considered to limit environmental exposure.
V skladu z dokumentom o presoji odbora CVMP o pridobitvi dovoljenja za promet z zdravili za uporabo v veterinarski medicini, ki vsebujejo snovi PBT ali vPvB (EMA/CVMP/448211/2015),17 je treba za omejevanje izpostavljenosti okolja preučiti še druge ukrepe za zagotavljanje odgovorne uporabe antiparazitskih zdravil za uporabo v veterinarski medicini, na primer ciljno in selektivno zdravljenje posameznih živali na ravni kmetije.
Given the limited number of different classes of end-/ectoparasiticides and the responsible use principle requiring the use of substances of different classes of antiparasitics for the control of parasitoses in order to reduce the risk of resistance development, veterinary medicinal products containing moxidectin are considered an important therapeutic option.
Glede na omejeno število različnih razredov endo-/ektoparaziticidov in načelo odgovorne uporabe, ki pri zatiranju parazitoz zahteva uporabo učinkovin iz različnih razredov antiparazitikov, da se zmanjša tveganje za razvoj odpornosti, veljajo zdravila za uporabo v veterinarski medicini, ki vsebujejo moksidektin, za pomembno terapevtsko možnost.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-target organisms:
Kot drugi makrociklični laktoni ima tudi moksidektin potencial, da negativno vpliva na neciljne organizme.
Zoetis Hungary Kft. 1123 Budapest Alkotás u. 53.
Madžarska Zoetis Hungary Kft. 1123 Budapest
The Tier A studies have been performed according to OECD standard guidelines.
Študije stopnje A so izvedli v skladu s standardnimi smernicami OECD.
Crustaceans (Water fleas)
Raki (vodne bolhe)
One major degradation product (>10% of applied radioactivity) was observed in all four soils which reached mean maximum levels of 37.81%, 29.12%, 42.97% and 31.14% of applied radioactivity, respectively.
V vseh štirih vrstah tal so opazili en večji produkt razgradnje (> 10 % dodane radioaktivnosti), ki je dosegel povprečne najvišje ravni dodane radioaktivnosti 37,81 %, 29,12 %, 42,97 % oziroma 31,14 %.
Additionally, data on faecal excretion were considered by the marketing authorisation holders for the justification of the proposed risk mitigation measures and warnings, respectively.
Poleg tega so imetniki dovoljenj za promet z zdravilom pri utemeljitvi predlaganih ukrepov za zmanjšanje tveganja oziroma opozoril preučili tudi podatke o izločanju z blatom.
The marketing authorisation holders argued that under realistic conditions, aquatic exposure to moxidectin will be either unlikely or extremely low due to strong adsorption of moxidectin onto soil or will not be maintained longer than 24 hours due to rapid partitioning into sediment.
Imetniki dovoljenj za promet z zdravilom so trdili, da je v realnih pogojih vodna izpostavljenost moksidektinu zelo malo verjetna ali izjemno majhna, in sicer zaradi močne adsorpcije moksidektina na tla, oziroma zaradi hitre porazdelitve v sediment ne bo trajala dlje kot 24 ur.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-target organisms, in particular aquatic organisms and dung fauna.
Kot drugi makrociklični laktoni ima tudi moksidektin potencial, da negativno vpliva na neciljne organizme, zlasti na vodne organizme in organizme v gnoju.
The CVMP considered the experimental study on bioaccumulation in fish in accordance with OECD guideline no. 305 the most appropriate and reliable reference for assessing the bioaccumulation potential of moxidectin.
Odbor CVMP je presodil, da je eksperimentalna študija kopičenja v ribah v skladu s smernico OECD št. 305 najprimernejša in najzanesljivejša referenca za ocenjevanje potenciala moksidektina za kopičenje v organizmih.
Thus, the Committee recommended warning sentences to be added to the product information, taking account of the risk of toxic residues in dung to dung fauna.
Zato je odbor priporočil, da se v informacije o zdravilu dodajo opozorilni stavki, da je treba upoštevati tveganje za ostanke v gnoju, ki so strupeni za organizme v gnoju.
The environmental profile of therapeutic alternatives including the group of macrocyclic lactones (ivermectin, abamectin, eprinomectin, and doramectin) and other groups of parasiticides such as organophosphates, synthetic pyrethroids and insect growth regulators has been considered based on available data.
Na podlagi razpoložljivih podatkov je bil preučen okoljski profil drugih terapevtskih možnosti, vključno s skupino makrocikličnih laktonov (ivermektin, abamektin, eprinomektin in doramektin) ter drugih skupin paraziticidov, kot so organofosfati, sintetični piretroidi in regulatorji rasti insektov.
The degradation of [3H]-moxidectin was investigated under aerobic conditions at 20±2 ºC for 120 days in the dark, following application at a nominal rate of 0.01 mg/kg soil to four different types of soil (i.e. sandy loam, sand, clay loam and loam with organic carbon content of 1.0%, 0.4%, 2.0% and 4.5%,
Razgradnjo [3H]moksidektina so preučevali pod aerobnimi pogoji pri 20 ± 2 ºC 120 dni v temi, po vnosu nazivne vsebnosti 0,01 mg/kg tal v štiri različne vrste tal (tj. peščeno-glinena, peščena, glineno-ilovnata in ilovnata z vsebnostjo organskega ogljika 1,0 %, 0,4 %, 2,0 % oziroma 4,5 % ter vsebnostjo vlage,
However, it has to be noted that other factors such as low moisture content also lead to reduced degradation.
Treba je opozoriti, da na zmanjšano razgradnjo vplivajo tudi drugi dejavniki, na primer nizka vsebnost vlage.
Moreover, in view of the need for a targeted field study to generate data on the fate and behaviour of moxidectin in different environmental compartments under actual use conditions and to verify that the likelihood of persistence, bioaccumulation and toxicity to occur in the environment is low, it is considered that conditions affecting the marketing authorisations should be imposed (see Annex IV).
Poleg tega je treba glede na potrebo po ciljni terenski študiji za pridobitev podatkov o končnem stanju in obnašanju moksidektina v različnih ekosistemih v pogojih dejanske uporabe in za preverjanje, ali je verjetnost za obstojnost, kopičenje v organizmih in strupenost v realnih pogojih majhna, uveljaviti pogoje, ki vplivajo na dovoljenja za promet z zdravilom (glejte Prilogo IV).
The Predicted No Effect Concentrations (PNECs) derived by dividing the most sensitive endpoints (LC50/EC50) for the most sensitive standard organism by an assessment factor of 100 amount to 4.7 and 10 µg/kg dry weight for the dung fly (Musca autumnalis) and the dung beetle (Aphodius constans), respectively.
Predvideni koncentraciji brez učinka (PNEC) so izračunali tako, da so delili vrednosti dveh najobčutljivejših opazovanih dogodkov (LC50/EC50) za najobčutljivejši standardni organizem s faktorjem ocenjevanja 100; to je pomenilo 4,7 µg/kg suhe teže pri jesenski muhi (Musca autumnalis) in 10 µg/kg pri iztrebkarju (Aphodius constans).
Apart from macrocyclic lactones, established classes of antiparasitics in cattle, sheep and horses include benzimidazoles, tetrahydropyrimidines (pyrantel), imidazothiazoles (levamisole), amino-acetonitril derivates (monepantel), spiroindoles (derquantel).
Poleg makrocikličnih laktonov uveljavljeni razredi antiparazitikov pri govedu, ovcah in konjih vključujejo benzimidazole, tetrahidropirimidine (pirantel), imidazotiazole (levamisol), aminoacetonitrilne derivate (monepantel) in spiroindole (derkantel).
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
6.6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z lokalnimi predpisi.
Thus, to verify the weight of evidence approach as proposed by the marketing authorisation holders, and to assess whether the theoretical hazards translate into environmental impacts, the CVMP considered that data on fate and behaviour of moxidectin in the environment under actual use conditions should be generated.
Torej je za preverjanje metode teže dokazov, kot predlagajo imetniki dovoljenj za promet z zdravilom, in za ocenjevanje, ali se teoretične nevarnosti preslikajo v vplive na okolje, odbor CVMP presodil, da je treba pridobiti podatke o končnem stanju in obnašanju moksidektina v okolju v pogojih dejanske rabe.
Equest 2% Oral Gel for Horses
Equest 2% Oral Gel for Horses moksidektin peroralni gel
The maximum PECsoil_initial equals 4.18 µg/kg dry weight for cattle after subcutaneous route of administration (injectable products) using a dose of 0.5 mg/kg bodyweight and the respective default values.
Najvišja vrednost PECtla_začetna znaša 4,18 µg/kg suhe teže za govedo po subkutanem vnosu (zdravila za injiciranje) z uporabo odmerka 0,5 mg/kg telesne mase in ustreznih privzetih vrednosti.
The NOECs for emergence ratio, the most sensitive study endpoint, were 235 μg/kg dry weight based on nominal sediment concentrations and 111 µg moxidectin equivalents/kg dry weight, respectively.
Vrednosti NOEC za koeficient preobrazbe, najobčutljivejši opazovani dogodek študije, sta bili 235 μg/kg suhe teže na podlagi nazivnih koncentracij v sedimentu oziroma 111 µg ekvivalentov moksidektina/kg suhe teže.
The subacute toxicity was investigated in a GLP compliant study according to US FDA Environmental Assessment Technical Assistance Document no. 4.1214.
Subakutno strupenost so preučevali v študiji, skladni z dobro laboratorijsko prakso in dokumentom za tehnično pomoč pri ocenjevanju vpliva na okolje ameriške agencije FDA št. 4.1214.
A qualitative risk assessment based on a weight of evidence discussion was provided and this considered the likelihood of persistence, bioaccumulation and toxicity to occur under real environmental conditions.
Predložena je bila kvalitativna ocena tveganja na podlagi razprave o teži dokazov, v kateri so ocenjevali verjetnost, da bo v realnih pogojih okolja prišlo do obstojnosti, kopičenja v organizmih in strupenosti.
EC50: the concentration which results in 50% of the test species individuals being adversely affected, i.e. both mortality and sub-lethal effects.
EC50: koncentracija, ki povzroči škodljive učinke, tj. umrljivost in subletalne učinke, pri 50 % pripadnikov testne vrste.
The CVMP considered the experimental laboratory study on [3H]-moxidectin transformation in soils in accordance with OECD guideline no. 307 the most reliable and appropriate reference for assessing the persistence of moxidectin in different soil types and determining the DT50 for the substance.
Odbor CVMP je presodil, da je eksperimentalna laboratorijska študija o pretvorbi [3H]-moksidektina v tleh v skladu s smernico OECD št. 307 najzanesljivejša in najprimernejša referenca za ocenjevanje obstojnosti moksidektina v različnih vrstah tal in določanje DT50 za snov.
The CVMP guideline on the assessment of PBT/vPvB substances in veterinary medicinal products (EMA/CVMP/ERA/52740/2012) suggests that the standard approach used to determine the risk to the environment associated with veterinary medicinal products (risk quotient approach, where a risk is characterised by calculating the Predicted Environmental Concentration (PEC)/Predicted No Effect Concentration (PNEC) ratio) is not appropriate for substances classified as PBT.
Smernica CVMP o ocenjevanju snovi PBT/vPvB v zdravilih za uporabo v veterinarski medicini (EMA/CVMP/ERA/52740/2012) navaja, da standardni pristop, ki se uporablja za ugotavljanje tveganja za okolje, povezanega z zdravili za uporabo v veterinarski medicini (metoda količnika tveganja, pri kateri se tveganje določi z izračunom razmerja med predvideno koncentracijo v okolju (PEC) in predvideno koncentracijo brez učinka (PNEC)), ni primeren za snovi, razvrščene med PBT.
The CVMP acknowledged that aquatic exposure might be low due to immobility of moxidectin in soil and rapid partitioning into sediment and consequently might reduce toxicity to aquatic organisms.
Odbor CVMP je priznal, da je vodna izpostavljenost zaradi imobilnosti moksidektina v tleh in hitre porazdelitve v sediment lahko majhna, kar lahko zmanjša strupenost za vodne organizme.
Taking into account all the information provided it can be concluded that moxidectin is highly toxic to dung fauna with dung fly being the most sensitive species.
Z upoštevanjem vseh predloženih informacij je mogoče zaključiti, da je moksidektin zelo strupen za organizme v gnoju, najobčutljivejša vrsta pa je jesenska muha.
The NOEC of moxidectin for reproduction in D. magna was therefore concluded to be >10 ng/l.
Zato so zaključili, da je vrednost NOEC moksidektina za razmnoževanje pri D. magna > 10 ng/l.
19,5 mg/g Horse
19,5 mg/g konji
The PBT hazard assessment clearly identifies moxidectin as a PBT substance based on the laboratory data provided.
Z oceno nevarnosti PBT je moksidektin na podlagi predloženih laboratorijskih podatkov jasno opredeljen kot snov PBT.
A tiered approach was applied considering the CVMP draft guideline on the higher tier testing of veterinary medicinal products to dung fauna (EMA/CVMP/ERA/409350/2010)13.
Uporabljen je bil stopenjski pristop z upoštevanjem osnutka smernice CVMP o višjestopenjskem testiranju zdravil za uporabo v veterinarski medicini na organizme v gnoju (EMA/CVMP/ERA/409350/2010)13.
• the CVMP considered that in order to reduce the identified risks for aquatic and sediment organisms, risk mitigation measures should be included in the product information.
• odbor CVMP je presodil, da je za zmanjšanje ugotovljenih tveganj za vodne organizme in organizme v sedimentu v informacije o zdravilu treba vključiti ukrepe za zmanjšanje tveganja.
The threshold specified in the CVMP guideline on the assessment of PBT/vPvB substances in veterinary medicinal products (EMA/CVMP/ERA/52740/2012) is NOEC or EC10 for marine or freshwater organisms less than 0.01 mg/l.
Mejna vrednost, določena v smernici CVMP o ocenjevanju snovi PBT/vPvB v zdravilih za uporabo v veterinarski medicini (EMA/CVMP/ERA/52740/2012), je NOEC ali EC10 za morske ali sladkovodne organizme, ki znaša manj kot 0,01 mg/l.
Consequently, given the limited number of different classes of end/ectoparasiticides, veterinary medicinal products containing moxidectin are an important therapeutic alternative to other veterinary medicinal products containing macrocyclic lactones.
Zato so zdravila za uporabo v veterinarski medicini, ki vsebujejo moksidektin, glede na omejeno število različnih razredov endo-/ektoparaziticidov pomembna terapevtska alternativa drugim zdravilom za uporabo v veterinarski medicini, ki vsebujejo makrociklične laktone.
As previously noted, and as outlined in the CVMP guideline on the assessment of PBT/vPvB substances in veterinary medicinal products (EMA/CVMP/ERA/52740/2012), a quantitative risk assessment is not appropriate for the PBT hazard assessment.
Kot že prej omenjeno in kot je navedeno v smernici CVMP o ocenjevanju snovi PBT/vPvB v zdravilih za uporabo v veterinarski medicini (EMA/CVMP/ERA/52740/2012), kvantitativna ocena tveganja ni ustrezna za ocenjevanje nevarnosti PBT.
An impact on dung flies was shown for all target species (cattle, sheep, and horses) and all routes of administration (pour-on, injectable, oral).
Vpliv na jesensko muho je bil dokazan pri vseh ciljnih vrstah (govedo, ovce in konji) in vseh poteh uporabe (kožni poliv, z injekcijo, peroralno).
The first study was conducted with [3H]-moxidectin and resulted in a NOEC and lowest observed effect concentration (LOEC) for reproduction as well as for parental growth at 0.0031 μg/l and 0.025 µg/l, respectively.
Prvo študijo so izvedli z [3H]-moksidektinom in določili vrednost NOEC kot 0,0031 μg/l in najnižjo koncentracijo z opaznim učinkom (LOEC) za razmnoževanje in starševsko rast kot 0,025 µg/l.
The NOEC for fry survival, the most sensitive study endpoint, was established as 3.2 ng/l.
Vrednost NOEC za preživetje mladic, najobčutljivejši opazovani dogodek študije, so določili kot 3,2 ng/l.
Although the efficacy of veterinary medicinal products containing moxidectin has not been re-assessed specifically in this referral procedure, these pour-on, injectable and oral products are considered effective veterinary medicines in the treatment of the abovementioned internal and external parasites in cattle, sheep and horses.
Čeprav učinkovitosti zdravil za uporabo v veterinarski medicini, ki vsebujejo moksidektin, v tem napotitvenem postopku niso izrecno ponovno ocenjevali, veljajo ta zdravila v obliki kožnega poliva, injekcij in peroralna zdravila za učinkovita zdravila za uporabo v veterinarskih zdravilih pri zdravljenju zgoraj navedenih notranjih in zunanjih parazitov pri govedu, ovcah in konjih.
The second biodegradation study with moxidectin was performed in three different soils (i.e. sandy loam, loam and silt loam with an organic carbon content of 0.58%, 1.39%, and 1.8%, respectively, and a moisture content maintained at 70% of the field capacity) at 25 °C under aerobic conditions for 63 days in the dark.
Drugo študijo biološke razgradljivosti z moksidektinom so izvedli v treh različnih vrstah tal (tj. peščeno-ilovnatih tleh z vsebnostjo organskega ogljika 0,58 %, ilovnatih tleh z vsebnostjo 1,39 % in muljasto-ilovnatih tleh z vsebnostjo 1,8 %, pri čemer so vsebnost vlage vzdrževali pri 70 % poljske kapacitete) pri 25 °C v aerobnih pogojih v obdobju 63 dni v temi.
BCFS = bioconcentration factor at steady state BCFSL = bioconcentration factor at steady state corrected for 5% lipid content BCFK = kinetic bioconcentration factor
BCFS = biokoncentracijski faktor v stanju dinamičnega ravnovesja BCFSL = biokoncentracijski faktor v stanju dinamičnega ravnovesja, korigiran na 5-odstotno vsebnost maščob BCFK = kinetični biokoncentracijski faktor
Zoetis Česká republika, s.r.o.
Slovaška Zoetis Česká republika, s.r.o.
Data on the fate and behaviour of moxidectin in the environment under real conditions to verify the proposed low likelihood of environmental impact are not available.
Podatki o končnem stanju in obnašanju moksidektina v okolju v realnih pogojih, s katerimi bi lahko preverili predlagano majhno verjetnost vpliva na okolje, niso na voljo.
For cattle, the highest PECs for surface water were 0.436 ng/l for run-off after subcutaneous route of administration (injectable products) and 0.219 ng/l for direct excretion into surface waters after topical (cutaneous) route of administration (pour-on products).
Pri govedu sta bili najvišji vrednosti PEC za površinske vode 0,436 ng/l pri odtekanju po subkutani uporabi (zdravila za injiciranje) in 0,219 ng/l pri neposrednem izločanju v površinske vode po topični (kožni) poti uporabe (zdravila v obliki kožnega poliva).
• the CVMP considered that veterinary medicinal products containing moxidectin to be administered to cattle, sheep and horses as pour-on, injectable and oral formulations are an important therapeutic alternative, given the limited number of different classes of end-/ectoparasiticides and the responsible use principle requiring the use of substances of different classes of antiparasitics for the control of parasitoses in order to reduce the risk of resistance development;
• odbor CVMP je presodil, da so zdravila za uporabo v veterinarski medicini, ki vsebujejo moksidektin, za dajanje govedu, ovcam in konjem v obliki kožnega poliva, injekcij in peroralnih formulacij glede na omejeno število različnih endo-/ektoparaziticidov in načelo odgovorne uporabe, ki pri zatiranju parazitoz zahteva uporabo učinkovin iz različnih razredov antiparazitikov, da se zmanjša tveganje za razvoj odpornosti, pomembna terapevtska možnost;
The effect of prolonged exposure of moxidectin on the early life stages of the fathead minnow, (Pimephales promelas), was investigated in a GLP compliant study according to OECD guideline no. 21011.
Učinek dolgotrajne izpostavljenosti moksidektinu na zgodnje razvojne stopnje tolstoglavega pisanca (Pimephales promelas) so preučevali v študiji, skladni z dobro laboratorijsko prakso in smernico OECD št. 21011.
Overall the CVMP considered that moxidectin fulfils the T criterion based on the high toxicity of moxidectin to aquatic organisms, i.e. a NOEC of 3.1 ng/l for Daphnia magna and a NOEC of 3.2 ng/l for fish (Pimephales promelas).
Na splošno je odbor CVMP presodil, da moksidektin izpolnjuje merilo strupenosti, in sicer na podlagi visoke strupenosti moksidektina za vodne organizme, tj. vrednosti NOEC 3,1 ng/l za Daphnia magna in vrednosti NOEC 3,2 ng/l za ribe (Pimephales promelas).
Thus, the standard risk assessment approach where the risk is characterised by calculating the PEC/PNEC ratio is not appropriate for PBT substances as outlined in the CVMP guideline on the assessment of PBT/vPvB substances in veterinary medicinal products (EMA/CVMP/ERA/52740/2012).
Zato standardni pristop za oceno tveganja, pri katerem se tveganje določa z izračunom razmerja PEC/PNEC, za snovi PBT ni primeren, kot je navedeno v smernici CVMP o ocenjevanju snovi PBT/vPvB v zdravilih za uporabo v veterinarski medicini (EMA/CVMP/ERA/52740/2012).
The second study in rainbow trout (Oncorhynchus mykiss), was performed in accordance with US FDA Environmental Assessment Technical Assistance Document no. 4.1110.
Druga študija na šarenki (Oncorhynchus mykiss) je bila opravljena v skladu z dokumentom za tehnično pomoč pri ocenjevanju vpliva na okolje ameriške agencije FDA št.
The assumption that the likelihood of persistence, bioaccumulation and toxicity occurring under real-world environmental conditions is low is based on theoretical considerations, as outlined above.
Domneva, da je verjetnost za obstojnost, kopičenje v organizmih in strupenost v realnih pogojih majhna, temelji na teoretičnih premislekih, kot je navedeno zgoraj.